1. Kaewkungwal J, Pitisuttithum P, Rerks-Ngarm S, Nitayaphan S, Khamboonruang C, Kunasol P, et al. Issues in women's participation in a phase III community HIV vaccine trial in Thailand. AIDS Res Hum Retroviruses. 2013; 29(11):1524-34. [MEDLINE] PMCID: 3809940. PMID: 23343395. doi: 10.1089/AID.2012.0265.
  2. Robb ML, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Kunasol P, et al. Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. Lancet Infect Dis. 2012; 12(7):531-7. [MEDLINE] PMCID: 3530398. PMID: 22652344. doi: 10.1016/S1473-3099(12)70088-9.
  3. Montefiori DC, Karnasuta C, Huang Y, Ahmed H, Gilbert P, de Souza MS, et al. Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis. 2012; 206(3):431-41. [MEDLINE] PMCID: 3392187. PMID: 22634875. doi: 10.1093/infdis/jis367.
  4. Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012; 28(11):1444-57. [MEDLINE] PMCID: 3484815. PMID: 23035746. doi: 10.1089/aid.2012.0103.
  5. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012; 366(14):1275-86. [MEDLINE] PMCID: 3371689. PMID: 22475592. doi: 10.1056/NEJMoa1113425.
  6. de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol. 2012; 188(10):5166-76. [MEDLINE] PMCID: 3383859. PMID: 22529301. doi: 10.4049/jimmunol.1102756.
  7. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012; 86(21):11521-32. [MEDLINE] PMCID: 3486290. PMID: 22896626. doi: 10.1128/JVI.01023-12.
  8. Rerks-Ngarm S, Premsri N, Namwat C, Khamboonruang C, Kunasol P, Pitisuttithum P, et al. Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine. 2011; 29(25):4285-92. [MEDLINE] PMID: 21435408. doi: 10.1016/j.vaccine.2011.03.014.
  9. Pitisuttithum P, Rerks-Ngarm S, Bussaratid V, Dhitavat J, Maekanantawat W, Pungpak S, et al. Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand. PLoS One. 2011; 6(12):e27837. [MEDLINE] PMCID: 3244387. PMID: 22205930. doi: 10.1371/journal.pone.0027837.
  10. Suntharasamai P, Martin M, Vanichseni S, Van Griensven F, Mock PA, Pitisuttithum P, et al. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999–2003. Addiction. 2009; 104(2):235-42. [MEDLINE] doi: 10.1111/j.1360-0443.2008.02436.x.
  11. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009; 361(23):2209-20. [MEDLINE] PMID: 19843557. doi: 10.1056/NEJMoa0908492.
  12. Pitisuttithum P, Rerks-Ngarm S, Kaewkungwal J, Nitayaphan S, Khamboonruang C, Kunasol P, et al. P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand. Retrovirology. 2009; 6(Suppl 3):P193. [MEDLINE] oi:10.1186/1742-4690-6-S3-P193.
  13. Kim J, Kamasuta C, Trichavaroj R, Kaewkungwal J, Chantakulkij S, Ratto-Kim S, et al. OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV(R) + AIDSVAX(R) B/E prime-boost vaccination in the Thai Phase III Trial. Retrovirology. 2009; 6(Suppl 3):O30. [MEDLINE] doi:10.1186/1742-4690-6-S3-O30.
  14. Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, Vimutisunthorn E, et al. Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX B/E HIV vaccine trial, Bangkok, Thailand. AIDS. 2004; 18(2):311-6. [MEDLINE] PMID: 15075550.
  15. van Griensvan F, Keawkungwal J, Tappero JW, Sangkum U, Pitisuttithum P, Vanichseni S, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS. 2004; 18(2):295-301. [MEDLINE] PMID: 15075548.
  16. Pitisuttithum P, Berman PW, Phonrat B, Suntharasamai P, Raktham S, Srisuwanvilai LO, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr. 2004; 37(1):1160-5. [MEDLINE] PMID: 15319676.
  17. Migasena S, Suntharasamai P, Pitisuttithum P, Kitayaporn D, Wasi C, Huang W, et al. AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization. AIDS Res Hum Retroviruses. 2000; 16(7):655-63. [MEDLINE] PMID: 10791876. DOI: 10.1089/088922200308882.